Timothy J. Hong, M.D., Hematologist/Medical Oncologist
Undergraduate: Harvard University - 1991 AB
Medical School: Yale University School of Medicine -1995 MD
Residency: Yale-New Haven Hospital 1995-1998 Internal Medicine
Fellowship: Duke University Medical Center 1999-2002 Hematology/Oncology
Assistant Clinical Professor at the University of Connecticut School of MedicineMember of the American Society of Clinical Oncology (ASCO)
Member of the American Society of Hematology (ASH)
GlaxoSmithKline Fellow in Clinical Pharmacology at Duke University Medical Center
Armstrong Fellow in Cancer at Duke University Medical Center
AREAS OF INTEREST
- Calvi, B.R., Hong, T.J., Findley, S.D., & Gelbart, W.M. (1991). Evidence for a common evolutionary origin of inverted repeat transposons in Drosophila and plants: hobo, Activator, and Tam3. Cell, 66, 465-471.
- Hong, T., Ortel, T., Truax, R., Walker, C., Bach, K., Swenson, C., Welles, L., & Hurwitz, H. (2002). A phase I pharmacokinetic dose-escalating trial of TLC ELL-12 in patients with refractory solid tumors. Proceedings of the American Society of Clinical Oncology, 21, 12b.
- Osada, T., Chong, G., Tansik, R., Hong, T., Spector, N., Kumar, R., Hurwitz, H.I., Dev, I., Nixon, A.B., Lyerly, H.K., Clay, T., & Morse, M.A. (2008). The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunology and Immunotherapy, 57, 1115-1124.